Bioymifi (Synonyms: DR5 Activator) |
| カタログ番号GC35523 |
強力な TRAIL 受容体 DR5 アクチベーターである Bioymifi (DR5 Activator) は、1.2 μM の Kd で DR5 の細胞外ドメイン (ECD) に結合します。 Bioymifi は、DR5 のクラスタリングと凝集を誘導する単一の薬剤として作用し、アポトーシスにつながります。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1420071-30-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bioymifi(DR5 Activator) is the first novel and potent small-molecule activatior of the TRAIL receptor DR5 in human cancer cells.IC50 value:Target: In comparison with A2C2, bioymifi was able to promote cell death without the need for the Smac mimetic in T98G cells. Notably, at a 10-μM concentration, bioymifi induced processing of caspase-3 into smaller fragments. Z-VAD inhibited these caspase-mediated cleavages. caspase-3 was rapidly activated as early as 2 h after bioymifi treatment of T98G cells. The caspase-3 activity was markedly increased after 8 h of treatment. Bioymifi induces caspase-8-dependent apoptosis.
[1]. Wang G, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013 Feb;9(2):84-9.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *